Estrogen receptor 1 gene polymorphisms and coronary artery disease in the Brazilian population

Brazilian Journal of Medical and Biological Research

Volumn 39, Issue 4, 2006, Pages 447-454

  Almeida, S ^a   Hutz, Mara H ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Coronary artery disease; ESR1 polymorphisms; Estrogen; Hormonal status

Indexed keywords

ADENINE; CYTOSINE; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR 1; GUANINE; THYMINE; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ANGIOCARDIOGRAPHY; ARTICLE; BRAZIL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY OBSTRUCTION; DISEASE SEVERITY; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HAPLOTYPE; HOMOZYGOSITY; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; POLYMERASE CHAIN REACTION; POPULATION GENETICS; PREVALENCE; RESTRICTION MAPPING; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 33645812891     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2006000400004     Document Type: Article

References (36)

1. Godsland IF (2001). Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertility and Sterility, 75: 898-915.
2. Mendelsohn ME & Karas RH (1999). The protective effects of estrogen on the cardiovascular system. New England Journal of Medicine, 340: 1801-1811.
3. Hopkins PN & Brinton EA (2003). Estrogen receptor 1 variants and coronary artery disease: shedding light into a murky pool. Journal of the American Medical Association, 290: 2317-2319.
4. Maas AH, van der Schouw YT, Grobbee DE et al. (2004). Rise and fall of hormone therapy in postmenopausal women with cardiovascular disease. Menopause, 11: 228-235.
5. Ohlsson C, Hellberg N, Parini P et al. (2000). Obesity and disturbed lipoprotein profile in estrogen receptor-α-deficient male mice. Biochemical and Biophysical Research Communications, 278: 640-645.
6. Hodgin JB, Krege JH, Reddick RL et al. (2001). Estrogen receptor α is a major mediator of 17β-estradiol's atheroprotective effects on lesion size in apoe-/- mice. Journal of Clinical Investigation, 107: 333-340.
7. Chen Z, Yuhanna IS, Galcheva-Gargova Z et al. (1999). Estrogen receptor α mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. Journal of Clinical Investigation, 103: 401-406.
8. Weel AEA, Uitterlinden AG, Westendorp ICD et al. (1999). Estrogen receptor polymorphism predicts the onset of natural and surgical menopause. Journal of Clinical Endocrinology and Metabolism, 84: 3146-3150.
9. Lorentzon M, Lorentzon R, Backstrom T et al. (1999). Estrogen receptor gene polymorphism, but not estradiol levels, is related to bone density in healthy adolescent boys: a cross-sectional and longitudinal study. Journal of Clinical Endocrinology and Metabolism, 84: 4597-4601.
10. Kobayashi S, Inoue S, Hosoi T et al. (1996). Association of bone mineral density with polymorphism of the estrogen receptor gene. Journal of Bone and Mineral Research, 11: 306-311.
11. Lehrer S, Rabin J, Kalir T et al. (1993). Estrogen receptor variant and hypertension in women. Hypertension, 21: 439-441.
12. Deng H-W, Li J, Li J-L et al. (2000). Association of estrogen receptor-α genotypes with body mass index in normal healthy postmenopausal Caucasian women. Journal of Clinical Endocrinology and Metabolism, 85: 2748-2751.
13. Herrington DM, Howard TD, Hawkins GA et al. (2002). Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. Journal of Clinical Endocrinology and Metabolism, 346: 967-974.
14. Herrington DM, Howard TD, Brosnihan KB et al. (2002). Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein. Circulation, 105: 1879-1882.
15. Lehtimäki T, Kunnas TA, Mattila KM et al. (2002). Coronary artery wall atherosclerosis in relation to the estrogen receptor 1 gene polymorphism: an autopsy study. Journal of Molecular Medicine, 80: 176-180.
16. Lu H, Higashikata T, Inazu A at al. (2002). Association of estrogen receptor-α gene polymorphisms with coronary artery disease in patients with familial hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 22: 1-7.
17. Nordström P, Glader CA, Dahlen G et al. (2003). Oestrogen receptor alpha gene polymorphism is related to aortic valve sclerosis in postmenopausal women. Journal of Internal Medicine, 254: 140-146.
18. Ferrero V, Ribichini F, Matullo G et al. (2003). Estrogen receptor-alpha polymorphisms and angiographic outcome after coronary artery stenting. Arteriosclerosis, Thrombosis, and Vascular Biology, 23: 2223-2228.
19. Shearman AM, Cupples LA, Demissie S et al. (2003). Association between estrogen receptor alpha gene variation and cardiovascular disease. Journal of the American Medical Association, 290: 2263-2270.
20. Schuit SC, Oei HH, Witteman JC et al. (2004). Estrogen receptor alpha gene polymorphisms and risk of myocardial infarction. Journal of the American Medical Association, 291: 2969-2977.
21. Lehtimäki T, Laaksonen R, Mattila KM et al. (2002). Oestrogen receptor gene variation is a determinant of coronary reactivity in healthy young men. European Journal of Clinical Investigation, 32: 400-404.
22. Koivu TA, Fan Y-M, Mattila KM et al. (2003). The effect of hormone replacement therapy on atherosclerotic severity in relation to ESR1 genotype in postmenopausal women. Maturitas, 44: 29-38.
23. Kunnas TA, Laippala P, Perittilä A et al. (2000). Association of polymorphism of human α oestrogen receptor gene with coronary artery disease in men: a necropsy study. British Medical Journal, 321: 273-274.
24. Kunnas TA, Lehtimäki T, Karhunen PJ et al. (2004). Estrogen receptor genotype modulates myocardial perfusion in young men. Journal of Molecular Medicine, 82: 821-825.
25. Rios DL, Vargas AF, Ewald GM et al. (2003). Common variants in the lipoprotein lipase gene in Brazil: association with lipids and angiographically assessed coronary atherosclerosis. Clinical Chemistry and Laboratory Medicine: CCLMIFESCC, 41: 1351-1356.
26. Lahiri DK & Nurnberger Jr JI (1991). A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Research, 19: 5444.
27. Yaich L, Dupont WD & Cavener DR (1992). Analysis of the Pvull restriction fragment-length polymorphism and exon structure of the estrogen receptor gene in breast cancer and peripheral blood. Cancer Research, 52: 77-83.
28. Andersen TI, Heimdal KR, Skrede M et al. (1994). Oestrogen receptor (ESR) polymorphisms and breast cancer susceptibility. Human Genetics, 94: 665-670.
29. Friedewald NT, Levy RI & Fredrickson DS (1972). Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry, 18: 499-502.
30. Abramson JH (2004). WINPEPI (PEPI-for-Windows): computer programs for epidemiologists. Epidemiologic Perspectives and Innovations, 1: 6.
31. Long JC, Williams RC & Urbanek M (1995). An E-M algorithm and testing strategy for multiple-locus haplotypes. American Journal of Human Genetics, 56: 799-810.
32. Long JC (1999). Multiple Locus Haplotype Analysis, Version 2.0. Software and documentation distributed by the author. Section on population genetics and linkage. Laboratory of Neurogenetics, NIAAA, National Institutes of Health, Bethesda, MD, USA.
33. Peterson RJ, Goldman D & Long JC (1999). Effects of worldwide population subdivision on ALDH2 linkage disequilibrium. Genome Research, 9: 844-852.
34. Schneider S, Kueffer J-M, Roessli D et al. (2000). Arlequin Version 2.000: A Software for Population Data Analysis. Genetics and Biometry Laboratory, University of Geneva, Geneva, Italy.
35. Lewontin RC (1988). On measures of gametic disequilibrium. Genetics, 120: 849-852.
36. Newton-Cheh C & O'Donnell CJ (2004). Sex differences and genetic associations with myocardial infarction. Journal of the American Medical Association, 291: 3008-3010.